World EPA Congress 2022

Life sciences organizations, especially emerging Biotech companies offering solutions in rare diseases, increasingly struggle with determining and communicating the optimal market value of innovations. 

Indegene will be at the World EPA Congress at Amsterdam in March this year, and talking about the impact of regulations and EU and UK environmental changes on PRMA in the innovative medicine and orphan drug space. 

You can also meet our experts at Booth #10.

22-24 March, 2022
Beurs Van Berlage, Amsterdam
EPA Congress

Our experts at booth #10

 
Jack M Mycka
Jack M Mycka
Vice President, PRMA & Emerging Biotech Commercialization
Indegene
Vikram Shanbhag
Vikram Shanbhag
Senior Director, PRMA and HEOR
Indegene
Nekshan Dalal
Nekshan Dalal
Senior Manager, PRMA
Indegene
 
 
 

What will be discussed?

Likely impact of EU4 & UK environmental changes on orphan PRMA

Potential impact of PRMA changes on innovative medicines

Proven solutions to identify and capture commercial value of assets

Our Sessions

  • Podium Session on "How much trouble ahead in orphan PRMA? Likely impact of EU4  & UK environmental changes", by Jack Mycka, VP, PRMA & Emerging Biotech Commercialization @Indegene, on 23rd March at 11:45 CET

  • Roundtable discussion - "Debating the potential impact of PRMA changes on innovative medicines in Europe", hosted by Jack Mycka, VP, PRMA & Emerging Biotech Commercialization @Indegene, on 23rd March at 13:55 CET

About the event

World EPA Congress 2022
March 22-24
Beurs Van Berlage, Amsterdam

World Evidence, Pricing and Access Congress is Europe’s largest congress in market access, pricing and evidence featuring 250 speakers, multiple streams and over 1000 attendees from pharma, biotech and Payers/HTA's.

Indegene is proud to be a silver sponsor at the event!

Visit the Website